Combination of Rituximab, Lenalidomide and Nivolumab for Relapsed/ Refractory Non-germinal Center (Non-GCB) Type Diffuse Large B Cell Lymphoma (DLBCL) Including Primary Central Nervous System Lymphoma (PCNSL): A Phase 1/2 Trial
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Nivolumab (Primary) ; Rituximab (Primary)
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Results from dose escalation cohort released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 23 Apr 2019 Status changed from recruiting to discontinued.
- 22 Jun 2018 New trial record